The New Cholesterol
The news that Esperion Therapeutics' drug, ETC-216, helped clear clogged arteries in an early-stage clinical trial is resonating throughout the drug industry. As the American Heart Association's annual meeting kicks off next week, discussions among cardiologists and drugmakers are likely to focus on the implications of Esperion's data.